Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study on the Safety of CLL-1-Targeted In Vivo CAR-T-Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia

NCT07841002 is registered in ClinicalTrials.gov with Liping Dou as lead sponsor.

NCT NCT07841002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07841002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study on the Safety of CLL-1-Targeted In Vivo CAR-T-Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia
Lead sponsor
Liping Dou
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
September 30, 2030
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), relapsed/refractory acute myeloid leukemia (aml)